On April 12th, 2022, bioMÃ©rieux acquired Specific Diagnostics, a USA-based company that developed a rapid antimicrobial
susceptibility test (AST) system that detects positive blood cultures.
bioMÃ©rieux has a strong portfolio of diagnostic products that can detect and identify bacterial infections. bioMÃ©rieux product line includes BIOFIRE® FILMARRAY®, BACT/ALERT® VIRTUO®, VITEK® MS, and VITEK® 2, This acquisition definitely helps bioMÃ©rieux
as they are into this business line for many years and compete more with companies like BD (Becton, Dickinson and Company) and Thermofisher as there is growing importance for the rapid AST testsing.
According to Precision Business Insights, Nosocomial Infections Testing Market is projected to reach close USD 3.5 Billion by 2024. Based on the global estimates, every year around 50 million sepsis cases reported across the globe and 5.4 million deaths every year.